Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.102.55
- Author:
Chang JIANG
1
;
Ling YI
2
;
Xiang GAO
1
;
Hongtao ZHANG
2
;
Shucai ZHANG
1
Author Information
1. Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University,
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
2. Department of Laboratory, Beijing Chest Hospital, Capital Medical University,
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
- Publication Type:Journal Article
- Keywords:
Biomarker;
Immunotherapy;
NSCLC;
PD-L1;
TMB
- MeSH:
B7-H1 Antigen;
Biomarkers, Tumor;
Carcinoma, Non-Small-Cell Lung/therapy*;
Humans;
Immunotherapy;
Lung Neoplasms/therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(1):46-53
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
.
